$EPRX News

Last published 1d ago

1d agoEPRXSTIFEL 2026 HEALTHCARE CONFERENCE - EUPRAXIA PHARMACEUTICALS INCEarnings Call TranscriptsGood afternoon, everyone, and thanks for joining the Eupraxia session. And with us today is James Hallowell, CEO of Eupaxia, and we have Alex Rothwell hiding in the corner, CFO. And Eupoxia has an interesting platform de
1d agoEPRXEupraxia Pharmaceuticals Establishes At-The-Market Offering ProgramGlobeNewswireVANCOUVER, British Columbia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that it has entered into a sales agreement (th ...
1d agoEPRXEupraxia Pharmaceuticals Reports Third Quarter 2026 Financial ResultsGlobeNewswireVANCOUVER, British Columbia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the third quarter of ...
2w agoEPRXEupraxia Pharmaceuticals (EPRX) Fireside Chat - EUPRAXIA PHARMACEUTICALS INCEarnings Call TranscriptsAll right. Good morning, everyone. I'm Albert Lo, Senior Biotech Analyst, and welcome to our Craig Hallen Biotec Conference. For our live viewers, please feel free to submit your questions on the webcast interface, and I
2w agoEPRXEupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst DayGlobeNewswireVANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging
3w agoEPRXEupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic EsophagitisGlobeNewswireEupraxia reached its target enrollment of 120 patients in the Phase 2b placebo-controlled blinded portion of the RESOLVE trialThe Company has a statistical team who are doing periodic reviews of the unblinded data to
1mo agoEPRXEupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical ConferencesGlobeNewswireVANCOUVER, British Columbia, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging
2mo agoEPRXEupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor ConferencesGlobeNewswireVANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging
3mo agoEPRXEupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis PatientsGlobeNewswireThe number of patients experiencing moderate to severe odynophagia (pain swallowing) in the cohorts analyzed (Cohorts 7-9) was reduced from 62% at baseline to 25% from 24 through to 52 weeks post treatmentIn the same
3mo agoEPRXEupraxia Pharmaceuticals Reports Second Quarter 2026 Financial ResultsGlobeNewswireNew data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI Strengthened executive team and board to bolster late-stage drug
4mo agoEPRXEupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of GrowthGlobeNewswireVANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging
4mo agoEPRXEupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and CommercializationGlobeNewswireVANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging
4mo agoEPRXEupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of ShareholdersGlobeNewswireVANCOUVER, British Columbia, June 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging
5mo agoEPRXEupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare ConferenceGlobeNewswireVANCOUVER, British Columbia, May 28, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its
6mo agoEPRXEupraxia Pharmaceuticals Reports First Quarter 2026 Financial ResultsGlobeNewswireRobust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Completion of a $63.2 million public offering to enable clinical trials of EP-104GI in additional indications
6mo agoEPRXEupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease WeekGlobeNewswireEoEHSS (EoE Histology Scoring System) is a standardized method used to monitor esophageal tissue damage in EoE patients. Sub scores of EoEHSS are reported to specifically evaluate the tissue inflammation and tissue
6mo agoEPRXEupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)GlobeNewswireEREFS is a standardized visual scoring system that gastroenterologists use when performing an endoscopy in EoE patients to assess the severity of inflammation and fibrosis in the esophagus EREFS data reported by
6mo agoEPRXEupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical OfficerGlobeNewswireVANCOUVER, British Columbia, May 01, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its
6mo agoEPRXEupraxia Pharmaceuticals to Present at Digestive Disease Week Annual MeetingGlobeNewswireVANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging
6mo agoEPRXEupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic EsophagitisGlobeNewswireThis is the first release of 36-week symptom response & tissue health data for the highest dose (Cohort 9) from the dose escalation portion of Eupraxia's RESOLVE trial. At 36 weeks, patients in Cohort 9 (n=3)
7mo agoEPRXEupraxia Pharmaceuticals to Present at Upcoming Investor ConferencesGlobeNewswireVICTORIA, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its
8mo agoEPRXEupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial ResultsGlobeNewswireVICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary
8mo agoEPRXEupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter OptionGlobeNewswireVICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary
8mo agoEPRXEupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded WarrantsGlobeNewswireVICTORIA, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary
8mo agoEPRXEupraxia Pharmaceuticals Announces Proposed Public OfferingGlobeNewswireVICTORIA, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary
10mo agoEPRXEupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on BiopsyGlobeNewswireAt week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health1.At lower doses, patients maintained the improvements in tissue
12mo agoEPRXEupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GIGlobeNewswireThe 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability data previously reported from Cohort 5; Cohorts 5 & 6 are the only groups to reach 52 weeks thus far.In Cohort 6, a
1y agoEPRXEupraxia Pharmaceuticals Reports Third Quarter 2025 Financial ResultsGlobeNewswireDurable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by Q3 2026 Completed
1y agoEPRXEupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development ProgramsGlobeNewswireClinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned in this trial. Patients in Cohort 9 experienced the largest improveme
1y agoEPRX HCNWF TAKOF WDOFFPeterson Capital Hosts Canada Growth Conference in IrelandGlobeNewswireDUBLIN, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Seven of Canada's fastest growing public companies will be gathering outside of Dublin today as they kick off the third Canada Growth Conference hosted by Edmonton-based
1y agoEPRXEupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter OptionGlobeNewswireVICTORIA, British Columbia, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary
1y agoEPRXEupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common SharesGlobeNewswireVICTORIA, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary
1y agoEPRXEupraxia Pharmaceuticals Announces Proposed Public Offering of Common SharesGlobeNewswireVICTORIA, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary
1y agoEPRXFirst Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GIGlobeNewswireAt 12 months, 2/3rds of Cohort 5 patients (48mg dose, 4mg per site) remained in clinical remission after their treatment with EP-104GIAll Cohorts followed to 9 months have maintained clinically meaningful improvements in
1y agoEPRXEupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireAnnounced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in H2 2026Announced positive data from Phase 1b/2a RESOLVE supporting the potential of
1y agoEPRXEupraxia Pharmaceuticals Invited to Present at Upcoming Investor ConferencesGlobeNewswireVICTORIA, British Columbia, July 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary
1y agoEPRXEupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of ShareholdersGlobeNewswireVICTORIA, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging its proprietary
1y agoEPFCF EPRX HNCUF REVVF+1"Bear-Pit Session" Highlights Peterson Capital's Canada Growth Conference in MontrealGlobeNewswireMONTREAL, May 15, 2025 (GLOBE NEWSWIRE) -- Nine public company CEOs stood the test of an entertaining and highly interesting "Bear-Pit" session at a two-day Canada Growth Conference that wound up in Montreal last
1y agoEPRXEupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025GlobeNewswireVICTORIA, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary
1y agoEPRXEupraxia Pharmaceuticals Reports First Quarter 2025 Financial ResultsGlobeNewswireData from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out to third quarter of
1y agoEPRXEupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GIGlobeNewswireEupraxia continues to observe positive treatment outcomes in its ongoing Phase 1b/2a trial, including for the first time clinical responses measured 9 months after dosing with EP-104GIAt 9 months active drug continued to
1y agoEPRXEupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and MayGlobeNewswireVICTORIA, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary
1y agoEPRXEupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial ResultsPR NewswireVICTORIA, BC, March 20, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage...
1y agoEPRXEupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisPR NewswireHistological scores and symptom scores continue to improve as EP-104GI dose, and area of esophageal coverage, increase Cohort 6 showed the greatest...
1y agoEPRXEupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six MonthsPR NewswireDiffuSphere™ is designed to enable precise drug delivery at therapeutic dose levels directly into target tissues, enhancing efficacy while minimizing ...
1y agoEPRXEupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual MeetingPR NewswireVICTORIA, BC, Nov. 14, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage...
1y agoEPRXEupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024PR NewswireEoE affects more than 450,000 people in the United States and has been identified by the American Gastroenterological Association as rapidly...
1y agoEPRXEupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisPR NewswireOne of three patients in Cohort 5 achieved complete histological remission at 12 weeks. Consistent improvement in patient-reported outcomes with six...
2y agoEPRXEupraxia Pharmaceuticals Reports Third Quarter 2024 Financial ResultsPR NewswireVICTORIA, BC, Nov. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage...
2y agoEPRXEupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 MillionPR NewswireVICTORIA, BC, Oct. 31, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage...